You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

CLINICAL TRIALS PROFILE FOR BETAMETHASONE DIPROPIONATE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for BETAMETHASONE DIPROPIONATE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00216827 ↗ Efficacy and Safety of Calcipotriol Plus Betamethasone Gel in the Treatment of Scalp Psoriasis Completed LEO Pharma Phase 3 2004-11-01 The purpose of this study is to evaluate whether once daily treatment for up to 8 weeks of calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) gel is safe and more effective than betamethasone 0.5 mg/g (as dipropionate) in the gel vehicle, calcipotriol 50 mcg/g in the gel vehicle or the gel vehicle used alone in patients with scalp psoriasis. The primary outcome is the proportion of patients with absence of disease or very mild disease after 8 weeks of treatment.
NCT00216840 ↗ Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Scalp Psoriasis Completed LEO Pharma Phase 3 2004-12-01 The purpose of the study is to evaluate whether once daily topical treatment for up to 8 weeks of calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) gel is safe and more effective than betamethasone 0.5 mg/g (as dipropionate) in the gel vehicle and calcipotriol 50 mcg/g in the gel vehicle in patients with scalp psoriasis. The primary response criterion is the number of patients with absence of disease and very mild disease after 8 weeks of treatment.
NCT00216879 ↗ Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel for up to a Year in Scalp Psoriasis Completed LEO Pharma Phase 3 2005-02-01 The purpose of the trial is to study the safety and efficacy of long term use of once daily applications, as needed, of calcipotriol plus betamethasone dipropionate gel, as compared to calcipotriol alone in the same gel. The primary response criteria will be the incidence of adverse drug reactions of any type, and the incidence of adverse events of concern associated with long-term corticosteroid use on the scalp.
NCT00216892 ↗ Efficacy and Safety of Calcipotriol Cream and (Calcipotriol + Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris Completed LEO Pharma Phase 4 2005-04-01 Patients with psoriasis vulgaris of the trunk and/or limbs are randomised to treatment with: 1. 4 weeks of ointment containing calcipotriol and betamethasone dipropionate followed by 8 weeks of calcipotriol cream 2. 4 weeks of (calcipotriol plus betamethasone dipropionate) ointment followed by 8 weeks of calcipotriol cream on weekdays/ (calcipotriol plus betamethasone dipropionate) ointment on weekends 3. 4 weeks of (calcipotriol plus betamethasone dipropionate) ointment followed by 8 weeks of vehicle of calcipotriol cream The objective is to compare the efficacy and safety of the different treatment regimens
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for BETAMETHASONE DIPROPIONATE

Condition Name

Condition Name for BETAMETHASONE DIPROPIONATE
Intervention Trials
Psoriasis Vulgaris 23
Psoriasis 10
Plaque Psoriasis 7
Psoriasis of Scalp 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for BETAMETHASONE DIPROPIONATE
Intervention Trials
Psoriasis 51
Syndrome 2
Dermatitis 2
Carpal Tunnel Syndrome 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for BETAMETHASONE DIPROPIONATE

Trials by Country

Trials by Country for BETAMETHASONE DIPROPIONATE
Location Trials
United States 137
Canada 20
United Kingdom 17
France 14
Japan 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for BETAMETHASONE DIPROPIONATE
Location Trials
Texas 12
California 10
Florida 9
Indiana 8
North Carolina 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for BETAMETHASONE DIPROPIONATE

Clinical Trial Phase

Clinical Trial Phase for BETAMETHASONE DIPROPIONATE
Clinical Trial Phase Trials
Phase 4 18
Phase 3 16
Phase 2/Phase 3 1
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for BETAMETHASONE DIPROPIONATE
Clinical Trial Phase Trials
Completed 52
Unknown status 7
Not yet recruiting 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for BETAMETHASONE DIPROPIONATE

Sponsor Name

Sponsor Name for BETAMETHASONE DIPROPIONATE
Sponsor Trials
LEO Pharma 34
Psoriasis Treatment Center of Central New Jersey 4
Encore Dermatology, Inc. 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for BETAMETHASONE DIPROPIONATE
Sponsor Trials
Industry 65
Other 24
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.